{{ infobox .infobox-gene
| gene = BSCL2
| name = BSCL2 Lipid Droplet Biogenesis Associated (Seipin) [1]
| chromosome = 11q13.1 [2]
| ncbi_gene_id = 27171 [3]
| ensembl = ENSG00000128590 [4]
| omim = 604158 [5]
| uniprot = O95456
| diseases = Hereditary Spastic Paraplegia 17, Berardinelli-Seip Congenital Lipodystrophy Type 2, Congenital Generalized Lipodystrophy
}}
BSCL2 (Berkman-Serpin Clade Homolog 2), also known as Seipin, is a crucial endoplasmic reticulum (ER) protein encoded by the BSCL2 gene on chromosome 11q13.1. This gene encodes a transmembrane protein that plays a fundamental role in lipid droplet biogenesis, ER homeostasis, and neuronal lipid metabolism. BSCL2 mutations are associated with two distinct clinical phenotypes: hereditary spastic paraplegia type 17 (HSP17), a neurodegenerative disorder characterized by progressive lower limb spasticity, and Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2), a rare autosomal recessive disorder marked by severe loss of adipose tissue and metabolic complications.
The seipin protein has garnered significant attention in neurodegeneration research due to its essential role in maintaining neuronal lipid homeostasis, particularly at synaptic terminals where lipid metabolism is critical for neurotransmitter release and membrane recycling.
Seipin is a key regulator of lipid droplet formation in eukaryotic cells. Located in the ER membrane, seipin forms oligomeric complexes that facilitate the nucleation and growth of lipid droplets 1. The protein contains a highly conserved domain that interacts with triglycerides and phospholipids, mediating the proper distribution of lipids between the ER membrane and nascent lipid droplets.
In adipocytes, seipin is essential for:
Seipin plays a critical role in maintaining ER morphology and function. Studies have shown that BSCL2 knockdown leads to altered ER structure, including dilated ER sheets and disrupted ER-mitochondria contacts 2. The protein interacts with several ER-resident proteins involved in lipid metabolism, including:
In neurons, seipin is particularly important for maintaining lipid homeostasis at synaptic terminals. The brain is enriched in lipids, with synaptic membranes requiring constant turnover and recycling of phospholipids and cholesterol. Seipin ensures proper lipid composition of synaptic vesicles and presynaptic membranes, which is essential for:
Research has demonstrated that BSCL2 is highly expressed in cortical and cerebellar neurons, with particular enrichment in Purkinje cells and hippocampal pyramidal neurons 3. This expression pattern suggests important roles in higher cognitive functions and motor coordination.
Seipin intersects with several key pathways implicated in neurodegenerative diseases:
Hereditary Spastic Paraplegia 17 (SPG17) is an autosomal recessive form of hereditary spastic paraplegia caused by BSCL2 mutations. This disorder is characterized by progressive spasticity and weakness of the lower limbs, with variable additional neurological features.
The core clinical manifestations of HSP17 include:
Many patients with HSP17 develop additional neurological manifestations:
Over 20 pathogenic BSCL2 mutations have been identified in HSP17 patients, including:
These mutations lead to loss of seipin function through various mechanisms:
The pathogenesis involves accumulation of ER stress, impaired lipid droplet function, and subsequent neuronal dysfunction in corticospinal tract neurons 4.
Currently, there is no disease-modifying therapy for HSP17. Management focuses on:
Berardinelli-Seip Congenital Lipodystrophy Type 2 (BSCL2) is a rare autosomal recessive disorder characterized by near-complete loss of adipose tissue from birth, leading to severe metabolic complications.
Recent studies have identified neurological involvement in BSCL2 patients:
The neurological manifestations may reflect both the metabolic consequences of lipodystrophy and direct effects of BSCL2 deficiency in the brain.
Recent research suggests potential involvement of BSCL2 in more common neurodegenerative diseases:
These associations are actively being investigated and may reveal new therapeutic targets 5.
BSCL2 is widely expressed throughout the brain with notable enrichment in:
BSCL2 expression data available from the Allen Brain Atlas:
Wang et al. Neuronal expression of seipin in the mouse brain (2015). 2015. ↩︎
Klein et al. Pathogenesis of BSCL2-related spastic paraplegia (2017). 2017. ↩︎
Liu et al. Seipin and neurodegenerative disease: new insights (2021). 2021. ↩︎
Berardinelli, Congenital generalized lipodystrophy: historical perspective (1954). 1954. ↩︎
Seip, Lipodystrophy: clinical classification (1991). 1991. ↩︎